Characterisation of steady‐state pharmacokinetics and glucodynamics of once‐weekly insulin efsitora alfa in individuals with type 2 diabetes
Open Access
- 23 February 2026
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (5) , 4010-4018
Abstract
Aims: To evaluate the steady‐state pharmacokinetics (PK) and glucodynamic effects of insulin efsitora alfa (efsitora) over a weekly interval in adults with type 2 diabetes (T2D). Materials and Methods: This open‐label, multiple dose, euglycaemic clamp study was conducted in 56 insulin naïve adults with T2D (mean [±SD] age, 61.9 ± 5.98 years; HbA1c, 7.1 ± 0.64%; BMI, 31.7 ± 3.20 kg/m 2 ). Following a dose‐finding lead‐in period with once‐daily degludec, eligible participants received a one‐time loading dose of 12 U/kg efsitora followed by 9 weekly doses of 4 U/kg. Three 24‐h clamps were conducted on Days 1, 4, and 7 after the last efsitora dose. Model‐based interpolation was used to derive the glucodynamic profile over the weekly dosing interval at steady‐state. Results: Model‐predicted pharmacokinetic steady‐state was achieved between the 4th and 6th weekly dose of efsitora when using a one‐time loading dose. At steady‐state, the PK profile over the week had a low peak‐to‐trough ratio of 1.16, with a half‐life of 19 days. The model‐predicted glucose infusion rate profile, over the weekly dosing interval, demonstrated a stable glucose‐lowering effect of efsitora. The maximum glucose infusion rate occurred between Days 4 and 5. Efsitora showed an even distribution of the glucose‐lowering effect within a weekly dosing interval, with a peak‐to‐trough ratio of 1.07. Efsitora was safe and well tolerated. Conclusions: Efsitora demonstrated a flat, prolonged PK profile, providing a consistent level of insulin exposure at steady‐state and resulting in a stable glucose‐lowering response across the weekly dosing interval.Keywords
Funding Information
- Eli Lilly and Company
This publication has 21 references indexed in Scilit:
- Low immunogenicity of insulin efsitora alfa in participants with type 1 and type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2025
- Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin TherapyNew England Journal of Medicine, 2025
- Safety, tolerability, pharmacokinetics and pharmacodynamics of GZR4 , a novel once‐weekly basal insulin, in healthy participants: A randomized trialDiabetes, Obesity and Metabolism, 2025
- Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin TreatmentNew England Journal of Medicine, 2024
- Understanding the Pharmacokinetics and Glucodynamics of Once Weekly Basal Insulins to Inform Dosing Principles: An Introduction to CliniciansEndocrine Practice, 2024
- Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 1 diabetesDiabetes, Obesity and Metabolism, 2024
- Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 2 diabetesDiabetes, Obesity and Metabolism, 2023
- American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 UpdateEndocrine Practice, 2022
- The future of insulin therapyDiabetes Research and Clinical Practice, 2021
- Insights into optimal basal insulin titration in type 2 diabetes: R esults of a quantitative surveyDiabetes, Obesity and Metabolism, 2017